Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ZNTL

Zentalis Pharmaceuticals Inc

Dec 13 • 04:00PM ET

3.09

Dollar change -0.04
Percentage change -1.28	%

Healthcare • Biotechnology • USA • NASD

Peers: BMY LLY PFE JNJ MRK AMGN GILD BIIB VRTX REGN

| Held by: VTI IWM VXF VB IWN IBB VBK SCHA VTWO DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.53	Insider Own	19.17%	Shs Outstand	71.15M	Perf Week	-11.71%
Market Cap	217.40M	Forward P/E	-	EPS next Y	-2.93	Insider Trans	-0.01%	Shs Float	57.60M	Perf Month	-21.17%
Income	-179.28M	PEG	-	EPS next Q	-0.79	Inst Own	83.16%	Short Float	8.11%	Perf Quarter	-16.03%
Sales	40.56M	P/S	5.36	EPS this Y	45.10%	Inst Trans	-14.56%	Short Ratio	2.21	Perf Half Y	-65.05%
Book/sh	4.98	P/B	0.62	EPS next Y	-19.28%	ROA	-34.60%	Short Interest	4.67M	Perf Year	-79.63%
Cash/sh	5.56	P/C	0.56	EPS next 5Y	-	ROE	-42.89%	52W Range	2.66 - 18.07	Perf YTD	-79.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-50.05%	ROI	-45.41%	52W High	-82.90%	Beta	1.85
Dividend TTM	-	Quick Ratio	7.29	Sales past 5Y	-20.00%	Gross Margin	96.77%	52W Low	16.17%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	7.29	EPS Y/Y TTM	45.45%	Oper. Margin	-515.94%	RSI (14)	42.20	Volatility	10.10% 8.89%
Employees	168	Debt/Eq	0.12	Sales Y/Y TTM	-	Profit Margin	-442.02%	Recom	1.89	Target Price	10.50
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	28.19%	Payout	-	Rel Volume	0.43	Prev Close	3.13
Sales Surprise	-	EPS Surprise	38.39%	Sales Q/Q	-	Earnings	Nov 06	Avg Volume	2.11M	Price	3.09
SMA20	-8.77%	SMA50	-6.89%	SMA200	-55.89%	Trades		Volume	906,515	Change	-1.28%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-12-24	Upgrade	Wedbush	Underperform → Neutral	$4
Jun-20-24	Downgrade	UBS	Buy → Neutral	$28 → $5
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-18-24	Downgrade	Wedbush	Neutral → Underperform	$15 → $4
Jun-18-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$38 → $8
Jun-18-24	Downgrade	Jefferies	Buy → Hold	$42 → $6
Nov-08-23	Downgrade	Wedbush	Outperform → Neutral	$38 → $12
Nov-07-23	Downgrade	Leerink Partners	Outperform → Market Perform	$15
Jul-12-22	Initiated	Cowen	Outperform
Apr-06-22	Initiated	Wells Fargo	Overweight	$67
Oct-07-21	Resumed	Jefferies	Buy	$120
Sep-30-21	Initiated	Stifel	Buy	$84
Sep-29-21	Initiated	Oppenheimer	Outperform	$90
May-21-21	Initiated	UBS	Buy	$91
Jan-20-21	Initiated	Wedbush	Outperform	$65
Sep-29-20	Initiated	Cantor Fitzgerald	Overweight	$44
Aug-27-20	Initiated	H.C. Wainwright	Buy	$43
Apr-28-20	Initiated	SVB Leerink	Outperform	$45
Apr-28-20	Initiated	Morgan Stanley	Overweight	$45
Apr-28-20	Initiated	Jefferies	Buy	$41

Show Previous Ratings

Dec-12-24 07:00AM	Zentalis Pharmaceuticals Announces Key Management Appointments (GlobeNewswire) -10.57%
Dec-02-24 04:35PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.20%
Nov-13-24 08:00AM	Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib (GlobeNewswire) +5.66%
Nov-01-24 07:04PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +21.61% +12.35%
Oct-18-24 03:05PM	State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings (GuruFocus.com)
03:03PM	Loading…
Oct-07-24 03:03PM	FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc (GuruFocus.com) -7.72%
Sep-17-24 12:15PM	FDA lifts partial clinical hold on Zentalis Pharmas cancer WEE1 inhibitor (Pharmaceutical Technology) +11.41%
Sep-16-24 09:00AM	FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers (Benzinga) +13.58%
07:00AM	Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies (GlobeNewswire)
Sep-09-24 07:00AM	Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024 (GlobeNewswire)
Sep-03-24 04:40PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.92%
Aug-26-24 11:58AM	Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why (Zacks)
Aug-09-24 02:53PM	ZNTL Stock Earnings: Zentalis Pharma Misses EPS for Q2 2024 (InvestorPlace) -9.37%
07:00AM	Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress (GlobeNewswire)
Aug-01-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.00%
06:00PM	Loading…
Jul-01-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -14.80%
Jun-19-24 10:23AM	Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold (Zacks)
04:52AM	FDA places partial clinical hold on Zentalis trials of azenosertib for cancer (Clinical Trials Arena)
Jun-18-24 07:00AM	Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program (GlobeNewswire) -50.66%
Jun-03-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-01-24 02:43AM	Insider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ... (GuruFocus.com)
May-30-24 07:00AM	Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-29-24 07:00AM	Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors (GlobeNewswire)
May-23-24 05:01PM	Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -5.84%
May-14-24 07:00AM	Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire)
May-08-24 10:27AM	Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating (MT Newswires)
May-07-24 09:04PM	Zentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ... (GuruFocus.com) +5.03%
01:54PM	ZNTL Stock Earnings: Zentalis Pharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress (GlobeNewswire)
May-01-24 05:30PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Loading…
Apr-02-24 04:05PM	Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024 (GlobeNewswire) -10.54% +8.25%
Apr-01-24 05:30PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-24 09:55AM	Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet (Zacks) +5.30%
07:00AM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-27-24 07:01PM	Zentalis Pharmaceuticals Inc (ZNTL) Reports Full Year 2023 Financial Results and Provides ... (GuruFocus.com)
07:00AM	Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates (GlobeNewswire)
Feb-14-24 09:35AM	Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL) (Zacks) +10.34%
Feb-13-24 07:00AM	Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference (GlobeNewswire) -5.83%
Feb-08-24 12:00PM	What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock (Zacks)
Feb-05-24 11:26PM	Insider Sell: President Cam Gallagher Sells 11,552 Shares of Zentalis Pharmaceuticals Inc (ZNTL) (GuruFocus.com)
Feb-01-24 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-25-24 07:00AM	Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments (GlobeNewswire)
Jan-08-24 07:00AM	Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform (Business Wire) +7.15%
Jan-02-24 04:49PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.54%
Dec-01-23 05:39PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-13-23 09:03PM	Director David Johnson's Strategic Purchase of Zentalis Pharmaceuticals Inc Shares (GuruFocus.com) +14.42%
Nov-09-23 07:00AM	Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen (GlobeNewswire)
Nov-06-23 07:13PM	Zentalis Pharmaceuticals Inc (ZNTL) Reports Q3 2023 Financial Results and Operational Updates (GuruFocus.com) -30.20% -18.27%
07:18AM	Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
Nov-01-23 04:52PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-07-23 05:00AM	Insider Sell: Chief Medical Officer Carrie Brownstein Sells 10,628 Shares of Zentalis ... (GuruFocus.com)
Oct-02-23 04:27PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-14-23 01:02AM	Director Jan Skvarka Sells 5,000 Shares of Zentalis Pharmaceuticals Inc (ZNTL) (GuruFocus.com)
Sep-06-23 07:00AM	Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Sep-01-23 04:37PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.34%
Aug-09-23 07:00AM	Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
Aug-01-23 04:28PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer (GlobeNewswire)
Jun-15-23 06:01AM	Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire) +12.67%
Jun-06-23 06:00AM	Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing (GlobeNewswire)
Jun-02-23 02:34PM	Why Shares of Zentalis Pharmaceuticals Dropped This Week (Motley Fool)
May-26-23 12:33PM	Wells Fargo Predicts up to 70% Rally for These 2 Stocks Heres Why They Have Solid Upside (TipRanks) +10.64%
10:53AM	Zentalis Gears Up for Phase 3 Study of Azenosertib after Positive Phase 1b Outcomes (Benzinga)
May-25-23 05:38PM	Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting (GlobeNewswire)
May-23-23 07:00AM	Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations (GlobeNewswire)
May-12-23 09:55AM	Wall Street Analysts Believe Zentalis Pharmaceuticals, Inc. (ZNTL) Could Rally 95.67%: Here's is How to Trade (Zacks)
May-10-23 07:00AM	Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates (GlobeNewswire) +6.93%
Apr-26-23 10:00AM	Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-17-23 09:00AM	Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023 (GlobeNewswire) +7.51%
Mar-01-23 07:00AM	Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates (GlobeNewswire)
Feb-13-23 07:00AM	Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer (GlobeNewswire)
Feb-01-23 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:01AM	Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Jan-17-23 09:18AM	We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely (Simply Wall St.)
Jan-03-23 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-08-22 09:55AM	Can Zentalis Pharmaceuticals, Inc. (ZNTL) Climb 170% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-01-22 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-22 07:00AM	Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates (GlobeNewswire) -21.98%
Nov-08-22 07:01AM	Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference (GlobeNewswire)
Nov-01-22 05:38PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-24-22 07:00AM	Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer (GlobeNewswire)
Oct-17-22 07:00AM	Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy (GlobeNewswire)
Oct-03-22 05:32PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-27-22 04:01PM	Zentalis Pharmaceuticals Promotes Co-Founder Kevin Bunker, Ph.D. to Chief Scientific Officer (GlobeNewswire)
Sep-19-22 07:00AM	Zentalis Pharmaceuticals Appoints Dr. Carrie Brownstein as Chief Medical Officer (GlobeNewswire)
Sep-12-22 07:00AM	Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors (GlobeNewswire)
Sep-01-22 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-31-22 07:00AM	Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-26-22 12:00PM	Zentalis Pharmaceuticals, Inc. (ZNTL) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-16-22 09:55AM	Does Zentalis Pharmaceuticals, Inc. (ZNTL) Have the Potential to Rally 129% as Wall Street Analysts Expect? (Zacks) -6.12%
Aug-10-22 04:39PM	This Analyst Says Zentalis' Increased Focus On WEE1 Program Is 'Prudent', Slashes Price Target By 37% (Benzinga) -8.65%
10:01AM	We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely (Simply Wall St.)
08:40AM	Why Zentalis Pharmaceuticals (ZNTL) Might Surprise This Earnings Season (Zacks)
Aug-09-22 04:01PM	Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update (GlobeNewswire)
Aug-03-22 07:00AM	Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Aug-01-22 05:10PM	Zentalis Pharmaceuticals, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-27-22 07:00AM	Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary (GlobeNewswire)
Jun-14-22 09:10AM	Billionaire Mario Gabelli is Dumping These 10 Stocks in 2022 (Insider Monkey)
Jun-01-22 07:00AM	Zentalis Pharmaceuticals to Participate in the Jefferies Healthcare Conference (GlobeNewswire)

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Diana Hausman	Former Chief Medical Officer	Oct 31 '24	Proposed Sale	2.86	9,888	28,294		Oct 31 08:59 PM
Vultaggio Vincent	Principal Accounting Officer	Oct 04 '24	Sale	3.18	1,603	5,098	33,855	Oct 04 06:01 PM
Gallagher Cam	President, Interim CFO	May 31 '24	Sale	11.98	9,597	114,972	633,680	May 31 06:27 PM
HAUSMAN DIANA	Chief Medical Officer	May 09 '24	Sale	12.62	3,356	42,353	373,876	May 09 07:46 PM
Epperly Melissa B,	Chief Financial Officer	Feb 12 '24	Sale	11.44	2,573	29,435	451,449	Feb 12 08:22 PM
Gallagher Cam	President	Feb 12 '24	Sale	11.44	1,173	13,419	643,277	Feb 12 08:21 PM
Lackner Mark	Chief Scientific Officer	Feb 02 '24	Sale	11.54	1,585	18,291	195,728	Feb 05 07:15 PM
Paul Andrea	Chief Legal Officer	Feb 02 '24	Sale	11.54	3,310	38,197	149,973	Feb 05 07:14 PM
Gallagher Cam	President	Feb 02 '24	Sale	11.54	11,552	133,310	644,450	Feb 05 07:13 PM
Epperly Melissa B,	Chief Financial Officer	Feb 02 '24	Sale	11.54	8,669	100,040	454,022	Feb 05 07:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZNTL

Zentalis Pharmaceuticals Inc

Upgrade your FINVIZ experience